Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trialAditya Bardia, Allyson J. Ocean, Linda T. Vahdat et al.|Annals of Oncology|2021Cited by 371
Survival outcomes of surgery and adjuvant chemotherapy in early-stage small cell and large cell lung cancer: a novel focus on tumors less than 1 cmJorge Raúl Vázquez-Urrutia, Takefumi Komiya, Junjia Zhu et al.|Discover Oncology|2025Cited by 5